News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim GmbH Ends Female Desire Drug Flibanserin Development After FDA's Safety Query


10/8/2010 7:45:59 AM

Oct. 8 (Bloomberg) - Boehringer Ingelheim GmbH abandoned development of its female desire drug flibanserin after U.S. regulators said the pill wasn’t proven to be safe and effective.

Read at Bloomberg
Read at Wall Street Journal
Read at Fox News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES